Post-spin dislocation at 3.9x P/E and 49% FCF yield, with Centerview-led strategic review and first-ever CEO insider purchase. Equity is a leveraged option on continued FCF ($160M+/yr), litigation containment and sale optionality. Floor softer than textbook asymmetry (no net cash, no tangible book), but anchored by durable consumables cash flow.
Primary method EV/EBITDA FY26E with risk-adjusted 6.5x multiple (vs peer median 10.8x). Cross-check with 10x TTM FCF indicates $7/sh equity (base). Implied EV/EBITDA at FV = 6.3x, within ±3% of nominal. Probability-weighted FV = 0.25×$20 + 0.45×$10 + 0.30×$3 = $10.40. Base case ($10) is above analyst mean PT ($4.00, Sep 25 2026) and above current price — difference driven by weight on strategic sale optionality that analysts do not credit. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Core diabetes consumables EV | $290M FY26E Adj EBITDA × 6.5x EV/EBITDA = $1,885M EV | +33.25 |
| Owen Mumford platform EV | $55M revenue FY27E × 2.0x EV/Sales = $110M EV (fresh integration) | +1.94 |
| Less: Net debt bridge | $1,469M debt − $218M cash = $1,251M / 56.7M sh | −22.06 |
| Strategic sale option value | 25% prob × $8/sh premium (Centerview process, 8-10x EBITDA bid) | +2.00 |
| Litigation reserve | Class action insulin pen: $300M expected × 50% prob / 56.7M sh | −2.64 |
| Shelf dilution reserve | Active $500M shelf, haircut −5% equity for refi dilution risk | −2.49 |
| FV base case | Sum: 33.25 + 1.94 − 22.06 + 2.00 − 2.64 − 2.49 = 10.00 | ≈ $10.00 |
Interpretation: 11.3% SI reflects skepticism on sale consummation and ongoing revenue decline. The combination of (a) heavy short positioning, (b) 90% institutional ownership, (c) CEO insider buying and (d) binary strategic-review catalyst sets up a classic asymmetric squeeze on positive news.
| Item ($M) | FY2024A | FY2025A | FY2026E | FY2027E | Guidance FY2026 |
|---|---|---|---|---|---|
| Revenue | 1,124 | 1,086 | 1,025 | 1,015 | $1,015–$1,035M |
| Gross Margin % | 65.2% | 62.6% | 58.0% | 58.5% | — |
| Adj EBITDA | 385 | 348 | 290 | 280 | Adj Op Mgn 23.5-24% |
| Adj EPS ($) | $2.65 | $2.15 | $1.85 | $1.75 | $1.80–$1.90 |
| Operating Cash Flow | 215 | 192 | 175 | 170 | — |
| Free Cash Flow | 190 | 170 | 160 | 155 | — |
| Net Debt | 1,210 | 1,180 | 1,251 | 1,120 | — |
| Metric | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 295.6 | 268.4 | 265.0 | 248.3 | 271.7 |
| Gross margin % | 66.7% | 63.1% | 60.2% | 57.1% | 56.4% |
| Adj EBITDA ($M) | 131.0 | 95.0 | 82.0 | 78.5 | 85.7 |
| End-of-period cash ($M) | 335 | 310 | 289 | 245 | 218 |
Business model — Diabetes care consumables + spin-off story
Core pen needles & syringes ~$880M FY26E (86% rev) 🔴 declining −8% YoY Market-leading disposables for insulin delivery. GM ~62%. Secular pressure from pump adoption (Insulet, Tandem) + GLP-1 therapy shift. Still generates $250M+ EBITDA on recurring consumables. Owen Mumford (acq. Jun 2026) ~$60-70M FY26E (6% rev) 🟢 ramping Safety injection devices and auto-injectors for pharma partners. GM target 50%+. $180M debt-funded acquisition. Platform for GLP-1 co-packaging and new high-margin revenue stream. GLP-1 co-packaging ~$85M FY26E (8% rev) 🟢 ramping Supplying pen needles bundled with GLP-1 injectables (Ozempic, Mounjaro, Wegovy). Live in India, Canada, Brazil. US launch targeted H1 2027. Partial offset to US pen-needle decline.
Legal, regulatory and risk analysis
SWOT analysis
- +#1 global share in pen needles (~40%), 100-year BD legacy brand
- +62% gross margins, recurring consumable revenue
- +$164M FCF TTM, 49% FCF yield on current market cap
- +International +11.5% offsets US weakness
- +Low capex intensity (~$30M/yr), stable working capital
- −$1.47B debt, negative tangible book (−$12/sh), 5.1x leverage
- −Core product (pen needles) in structural volume decline
- −Thin float (56.7M shares); 90% institutional concentration
- −Litigation overhang from 2026 insulin pen reliability issues
- −Gross margin compression from 66.7% to 56.4% in one year
- →Strategic sale at 9-10x EBITDA → equity value $18-22/sh
- →GLP-1 co-packaging rollout: India/Canada/Brazil live; US next H1 2027
- →Owen Mumford auto-injector platform (new high-margin revenue)
- →Multiple expansion if revenue stabilizes above $1.0B
- →Short-squeeze setup: 11.3% SI + binary catalyst density
- !Pump adoption accelerating (Insulet Omnipod 5, Tandem Mobi)
- !GLP-1 adoption may reduce chronic insulin usage long-term
- !Litigation outcome binary — reserve could prove inadequate
- !Covenant breach risk if FY27 EBITDA falls below $260M
- !Sale process failure → re-rating down to analyst PT $4
Summary by assessment area
- 100-year #1 franchise at 3.9x P/E, 5.3x EV/EBITDA, 49% FCF yield
- Centerview sale process + CEO insider buy = tangible re-rating catalyst
- Floor softer than textbook; anchored by $160M+ annual FCF
- Base $10 (+73%), Bull $20 (+245%), Bear $3 (−48%)
- Prob-weighted FV $10.40; ratio upside/downside ≈ 2.4x — passes
- Position-sizing must respect debt + litigation tail risk
- Q4 FY26 earnings 2026-11-24 — first FY27 guidance datapoint
- Centerview update expected within Q4 2026 – Q1 2027
- Lead plaintiff deadline ~2026-10-31; Form 4 watch post-earnings
Sources: StockAnalysis.com, Stocktitan.net, CNN Markets, TheDesperateTrader.com, SEC filings (Form 4 CEO Kurdikar 2026-08-12, 8-K Q3 2026 earnings 2026-08-07), TheCerbatGem (insider filings), Benzinga/TradingView (Centerview sale report). Market data — last verified close 2026-10-01: EMBC ~$5.79, market cap ~$328M, 52W $2.77–$14.91, 56.7M shares outstanding. Short interest: 11.3% of float. ASIMMETRIA mode run — DD generated 2026-10-02. This document is for informational purposes only and does not constitute financial or investment advice.